Company valuation ยท Healthcare

NRC: Hold + Reduce with a $15.62 price target

National Research Corp. More cash remains for each dollar of profit, but the latest quarter was loss-making.

Model target ยท USD
$15.62
For 2027-09-23
Model rating
Hold + Reduce
Reviewed 2026-09-22
Reference weekly close
$20.56
2026-09-18 ยท USD
Editorial illustration of National Research Corp, Health Information Services.
Generated editorial illustration for Sharemaestro. It does not depict verified company premises or events.

Investment view

More cash remains for each dollar of profit, but the latest quarter was loss-making.

Target and reference price

Target for 2027-09-23: $15.62 USD, -24.1% versus the $20.56 weekly close on 2026-09-18. Price return only; dividends, fees and tax excluded.

Price and earnings

Over 1 year (2025-09-19 to 2026-09-18), price changed +38.9% and trailing EPS changed -6.3%. A wider gap changes the earnings multiple; it does not establish fair value.

Supporting evidence

Cash after capital spending / profit: 3.7ร— for NRC, against 2.6ร— across 4 comparable peers.

Over one year, the stock changed +38.9% against +14.8% for US stocks (SPY). The gap is +24.2 percentage points. These are price returns, before dividends.

Risks to the case

Net income was -3.3m, compared with -0.1m in the same quarter last year. Amounts are in USD.

The latest quarterly operating margin was -9.1%, -13.8 percentage points from a year earlier. The full report separates sales growth from margin changes.

What to monitor

The latest quarterly margin changed -13.8 percentage points from a year earlier. Check sales volumes, pricing and unusual gains in the next filing.

Recheck the valuation gap alongside profitability and growth after new results. A discount alone does not establish value.

Compare the stock and the market fund over the same dates. Look for a change in relative performance as results arrive.

Valuation assumptions

Starting annual sales growth: 0.18%.

Long-term operating margin: 25.78%.

About this assessment

Review recorded on 2026-09-22. This is a dated summary of an automated company valuation. The full report includes the financial evidence, alternative scenarios and review history. Consult the latest report before using an earlier target. Automated model research, not personal investment advice. Targets depend on assumptions; returns are not guaranteed.

Evidence context